Key Points
- The first participants have been enrolled in a pivotal clinical trial for the treatment of chronic pain.
- Researchers are using SPIRE Therapeutic’s DIADEM device to apply low-intensity focused ultrasound neuromodulation to the limbic regions of the brain.
A new research study (NCT 07226648) is testing whether LIFU neuromodulation applied with SPIRE Therapeutic’s DIADEM device can reduce pain symptoms following modulation of the brain’s limbic circuits. Data collection is now proceeding at multiple sites across the United States.
For more information on the specific types of pain targeted in this study, visit clinicaltrials.gov.
“The goal of this clinical trial is to provide a measurable decrease in pain over the treatment period,” said Jan Kubanek, PhD, the co-founder of SPIRE Therapeutics. “The study is using a sham comparison to allow us to determine whether active stimulation provides significantly stronger and clinically meaningful improvements in pain intensity.”
The clinical trial is being funded by the Focused Ultrasound Foundation and SPIRE Therapeutics.
For Patients
Learn More on ClinicalTrials.gov or contact the trial’s principaI investigator, Akiko Okifuji, PhD, at Akiko.Okifuji@hsc.utah.edu.
Related Stories
Chronic Pain and Depression: Two Focused Ultrasound Clinical Trials Published November 2024
SPIRE Deploys Effective, Safe Ultrasonic Neuromodulation Device May 2024
Company Profile: SPIRE April 2024